STOCK TITAN

[Form 4] Agenus Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Embrace Change Acquisition Corp (EMCG) will hold an EGM on 11 Aug 2025 to vote on three items: (1) a charter amendment extending the deadline to close a business combination by 12 months to 12 Aug 2026; (2) a parallel amendment to the trust agreement; and (3) authority to adjourn if needed.

The SPAC has already paid for three one-month extensions (total $225k) but skipped eight required payments, creating $675k in arrears. Passage of the proposals would allow the board to extend without depositing further funds. Failure triggers mandatory redemption and liquidation within five business days.

Shareholders may redeem at approximately $12.08 per share versus the 25 Jul 2025 Nasdaq price of $12.15; the trust currently holds $26.9 m. The sponsor and insiders control 49.2 % of outstanding shares and cannot redeem. The extension amendment needs a two-thirds vote; the trust amendment needs a simple majority of votes cast.

Embrace Change Acquisition Corp (EMCG) terrà un'Assemblea Straordinaria degli Azionisti l'11 agosto 2025 per votare su tre punti: (1) una modifica dello statuto per estendere di 12 mesi, fino all'11 agosto 2026, il termine per completare una combinazione aziendale; (2) una modifica parallela all'accordo fiduciario; e (3) l'autorizzazione a rinviare la riunione se necessario.

La SPAC ha già pagato tre estensioni mensili (per un totale di 225.000 $) ma ha saltato otto pagamenti obbligatori, accumulando 675.000 $ di arretrati. L'approvazione delle proposte permetterebbe al consiglio di amministrazione di estendere il termine senza dover versare ulteriori fondi. In caso contrario, scatterebbe il rimborso obbligatorio e la liquidazione entro cinque giorni lavorativi.

Gli azionisti possono riscattare a circa 12,08 $ per azione, a fronte del prezzo Nasdaq del 25 luglio 2025 di 12,15 $; il fondo fiduciario detiene attualmente 26,9 milioni $. Lo sponsor e gli insider controllano il 49,2% delle azioni in circolazione e non possono riscattare. La modifica allo statuto richiede una maggioranza qualificata di due terzi; la modifica all'accordo fiduciario necessita di una maggioranza semplice dei voti espressi.

Embrace Change Acquisition Corp (EMCG) celebrará una Junta General Extraordinaria el 11 de agosto de 2025 para votar sobre tres puntos: (1) una enmienda al estatuto para extender el plazo para cerrar una combinación de negocios por 12 meses, hasta el 12 de agosto de 2026; (2) una enmienda paralela al acuerdo fiduciario; y (3) la autorización para aplazar la reunión si es necesario.

La SPAC ya pagó tres extensiones mensuales (total 225,000 $) pero omitió ocho pagos obligatorios, acumulando 675,000 $ en mora. La aprobación de las propuestas permitiría a la junta extender sin depositar fondos adicionales. El incumplimiento desencadena el reembolso obligatorio y la liquidación en un plazo de cinco días hábiles.

Los accionistas pueden redimir aproximadamente a 12.08 $ por acción frente al precio de Nasdaq del 25 de julio de 2025 de 12.15 $; el fideicomiso actualmente posee 26.9 millones $. El patrocinador y los insiders controlan el 49.2% de las acciones en circulación y no pueden redimir. La enmienda estatutaria requiere un voto de dos tercios; la enmienda al fideicomiso requiere mayoría simple de los votos emitidos.

Embrace Change Acquisition Corp (EMCG)는 2025년 8월 11일 임시주주총회를 개최하여 세 가지 안건에 대해 투표할 예정입니다: (1) 사업 결합 마감 기한을 12개월 연장하여 2026년 8월 12일까지로 하는 정관 개정; (2) 신탁 계약에 대한 병행 개정; (3) 필요 시 회의 연기 권한 부여.

SPAC는 이미 세 차례 한 달 연장에 대해 총 225,000달러를 지불했으나, 필수 납부금 8회를 건너뛰어 675,000달러의 체납금을 발생시켰습니다. 제안안이 통과되면 이사회는 추가 자금 납입 없이 연장할 수 있습니다. 실패 시에는 의무 상환 및 5영업일 이내 청산이 진행됩니다.

주주는 2025년 7월 25일 나스닥 가격인 12.15달러에 비해 약 12.08달러에 주식을 상환할 수 있으며, 신탁에는 현재 2,690만 달러가 보관 중입니다. 스폰서와 내부자는 발행 주식의 49.2%를 보유하고 있어 상환할 수 없습니다. 정관 개정은 3분의 2 이상의 찬성표가 필요하며, 신탁 개정은 출석한 투표의 단순 과반수 찬성이 필요합니다.

Embrace Change Acquisition Corp (EMCG) tiendra une assemblée générale extraordinaire le 11 août 2025 pour voter sur trois points : (1) une modification des statuts prolongeant de 12 mois la date limite pour conclure une fusion d'entreprise, jusqu'au 12 août 2026 ; (2) une modification parallèle de l'accord de fiducie ; et (3) l'autorisation de reporter la réunion si nécessaire.

La SPAC a déjà payé trois prolongations d'un mois (total 225 000 $) mais a omis huit paiements obligatoires, accumulant 675 000 $ d'arriérés. L'adoption des propositions permettrait au conseil d'administration de prolonger sans verser de fonds supplémentaires. En cas d'échec, un remboursement obligatoire et une liquidation doivent être effectués sous cinq jours ouvrables.

Les actionnaires peuvent racheter à environ 12,08 $ par action contre un cours Nasdaq au 25 juillet 2025 de 12,15 $ ; la fiducie détient actuellement 26,9 millions $. Le sponsor et les initiés contrôlent 49,2 % des actions en circulation et ne peuvent pas racheter. La modification des statuts nécessite un vote aux deux tiers ; la modification de la fiducie requiert une majorité simple des voix exprimées.

Embrace Change Acquisition Corp (EMCG) wird am 11. August 2025 eine außerordentliche Hauptversammlung abhalten, um über drei Punkte abzustimmen: (1) eine Satzungsänderung zur Verlängerung der Frist für den Abschluss einer Unternehmenszusammenführung um 12 Monate bis zum 12. August 2026; (2) eine parallele Änderung des Treuhandvertrags; und (3) die Befugnis zur Vertagung bei Bedarf.

Die SPAC hat bereits drei einmonatige Verlängerungen bezahlt (insgesamt 225.000 $), jedoch acht erforderliche Zahlungen ausgelassen, wodurch 675.000 $ rückständig sind. Die Annahme der Vorschläge würde dem Vorstand erlauben, ohne weitere Einzahlungen zu verlängern. Ein Scheitern löst eine obligatorische Rückzahlung und Liquidation innerhalb von fünf Werktagen aus.

Aktionäre können zu etwa 12,08 $ pro Aktie einlösen, verglichen mit dem Nasdaq-Kurs vom 25. Juli 2025 von 12,15 $; der Treuhandfonds hält derzeit 26,9 Mio. $. Der Sponsor und Insider kontrollieren 49,2 % der ausstehenden Aktien und können nicht einlösen. Die Satzungsänderung erfordert eine Zweidrittelmehrheit; die Treuhandänderung eine einfache Mehrheit der abgegebenen Stimmen.

Positive
  • Extension avoids immediate liquidation, maintaining the possibility of a value-creating business combination.
  • Redemption option at $12.08 offers near-market liquidity for holders preferring cash exit.
Negative
  • $675k in missed sponsor deposits highlights funding and governance concerns.
  • Extension requires no additional sponsor contribution, marginally diluting trust value for non-redeeming shareholders.
  • If proposals fail, mandatory redemption and dissolution will occur within five business days.

Insights

TL;DR: Extension buys EMCG 12 more months to find a deal, but missed sponsor deposits cloud confidence; overall market impact likely muted.

The proposal preserves the option value of the SPAC for public holders who believe a target can still be sourced. Extending without further $75k monthly deposits conserves sponsor cash, yet slightly dilutes residual trust per share for investors who stay. Redemption price is near-par, limiting arbitrage pressure. With 49 % insider ownership, passage appears likely, implying low risk of forced liquidation in August. However, failure would return ~$26.9 m to holders within days.

TL;DR: Sponsor’s $675k arrears raise governance red flags; extension sans payment shifts cost to public holders—negative for minority investors.

The sponsor’s failure to honor eight monthly deposits breaches prior obligations and signals potential funding strain. Allowing an additional 12-month runway without replenishing the trust reduces the economic cushion supporting public shares and sets a weak precedent for fiduciary discipline. Investors should weigh the governance risk against the upside of a yet-to-be-identified merger.

Embrace Change Acquisition Corp (EMCG) terrà un'Assemblea Straordinaria degli Azionisti l'11 agosto 2025 per votare su tre punti: (1) una modifica dello statuto per estendere di 12 mesi, fino all'11 agosto 2026, il termine per completare una combinazione aziendale; (2) una modifica parallela all'accordo fiduciario; e (3) l'autorizzazione a rinviare la riunione se necessario.

La SPAC ha già pagato tre estensioni mensili (per un totale di 225.000 $) ma ha saltato otto pagamenti obbligatori, accumulando 675.000 $ di arretrati. L'approvazione delle proposte permetterebbe al consiglio di amministrazione di estendere il termine senza dover versare ulteriori fondi. In caso contrario, scatterebbe il rimborso obbligatorio e la liquidazione entro cinque giorni lavorativi.

Gli azionisti possono riscattare a circa 12,08 $ per azione, a fronte del prezzo Nasdaq del 25 luglio 2025 di 12,15 $; il fondo fiduciario detiene attualmente 26,9 milioni $. Lo sponsor e gli insider controllano il 49,2% delle azioni in circolazione e non possono riscattare. La modifica allo statuto richiede una maggioranza qualificata di due terzi; la modifica all'accordo fiduciario necessita di una maggioranza semplice dei voti espressi.

Embrace Change Acquisition Corp (EMCG) celebrará una Junta General Extraordinaria el 11 de agosto de 2025 para votar sobre tres puntos: (1) una enmienda al estatuto para extender el plazo para cerrar una combinación de negocios por 12 meses, hasta el 12 de agosto de 2026; (2) una enmienda paralela al acuerdo fiduciario; y (3) la autorización para aplazar la reunión si es necesario.

La SPAC ya pagó tres extensiones mensuales (total 225,000 $) pero omitió ocho pagos obligatorios, acumulando 675,000 $ en mora. La aprobación de las propuestas permitiría a la junta extender sin depositar fondos adicionales. El incumplimiento desencadena el reembolso obligatorio y la liquidación en un plazo de cinco días hábiles.

Los accionistas pueden redimir aproximadamente a 12.08 $ por acción frente al precio de Nasdaq del 25 de julio de 2025 de 12.15 $; el fideicomiso actualmente posee 26.9 millones $. El patrocinador y los insiders controlan el 49.2% de las acciones en circulación y no pueden redimir. La enmienda estatutaria requiere un voto de dos tercios; la enmienda al fideicomiso requiere mayoría simple de los votos emitidos.

Embrace Change Acquisition Corp (EMCG)는 2025년 8월 11일 임시주주총회를 개최하여 세 가지 안건에 대해 투표할 예정입니다: (1) 사업 결합 마감 기한을 12개월 연장하여 2026년 8월 12일까지로 하는 정관 개정; (2) 신탁 계약에 대한 병행 개정; (3) 필요 시 회의 연기 권한 부여.

SPAC는 이미 세 차례 한 달 연장에 대해 총 225,000달러를 지불했으나, 필수 납부금 8회를 건너뛰어 675,000달러의 체납금을 발생시켰습니다. 제안안이 통과되면 이사회는 추가 자금 납입 없이 연장할 수 있습니다. 실패 시에는 의무 상환 및 5영업일 이내 청산이 진행됩니다.

주주는 2025년 7월 25일 나스닥 가격인 12.15달러에 비해 약 12.08달러에 주식을 상환할 수 있으며, 신탁에는 현재 2,690만 달러가 보관 중입니다. 스폰서와 내부자는 발행 주식의 49.2%를 보유하고 있어 상환할 수 없습니다. 정관 개정은 3분의 2 이상의 찬성표가 필요하며, 신탁 개정은 출석한 투표의 단순 과반수 찬성이 필요합니다.

Embrace Change Acquisition Corp (EMCG) tiendra une assemblée générale extraordinaire le 11 août 2025 pour voter sur trois points : (1) une modification des statuts prolongeant de 12 mois la date limite pour conclure une fusion d'entreprise, jusqu'au 12 août 2026 ; (2) une modification parallèle de l'accord de fiducie ; et (3) l'autorisation de reporter la réunion si nécessaire.

La SPAC a déjà payé trois prolongations d'un mois (total 225 000 $) mais a omis huit paiements obligatoires, accumulant 675 000 $ d'arriérés. L'adoption des propositions permettrait au conseil d'administration de prolonger sans verser de fonds supplémentaires. En cas d'échec, un remboursement obligatoire et une liquidation doivent être effectués sous cinq jours ouvrables.

Les actionnaires peuvent racheter à environ 12,08 $ par action contre un cours Nasdaq au 25 juillet 2025 de 12,15 $ ; la fiducie détient actuellement 26,9 millions $. Le sponsor et les initiés contrôlent 49,2 % des actions en circulation et ne peuvent pas racheter. La modification des statuts nécessite un vote aux deux tiers ; la modification de la fiducie requiert une majorité simple des voix exprimées.

Embrace Change Acquisition Corp (EMCG) wird am 11. August 2025 eine außerordentliche Hauptversammlung abhalten, um über drei Punkte abzustimmen: (1) eine Satzungsänderung zur Verlängerung der Frist für den Abschluss einer Unternehmenszusammenführung um 12 Monate bis zum 12. August 2026; (2) eine parallele Änderung des Treuhandvertrags; und (3) die Befugnis zur Vertagung bei Bedarf.

Die SPAC hat bereits drei einmonatige Verlängerungen bezahlt (insgesamt 225.000 $), jedoch acht erforderliche Zahlungen ausgelassen, wodurch 675.000 $ rückständig sind. Die Annahme der Vorschläge würde dem Vorstand erlauben, ohne weitere Einzahlungen zu verlängern. Ein Scheitern löst eine obligatorische Rückzahlung und Liquidation innerhalb von fünf Werktagen aus.

Aktionäre können zu etwa 12,08 $ pro Aktie einlösen, verglichen mit dem Nasdaq-Kurs vom 25. Juli 2025 von 12,15 $; der Treuhandfonds hält derzeit 26,9 Mio. $. Der Sponsor und Insider kontrollieren 49,2 % der ausstehenden Aktien und können nicht einlösen. Die Satzungsänderung erfordert eine Zweidrittelmehrheit; die Treuhandänderung eine einfache Mehrheit der abgegebenen Stimmen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
ARMEN GARO H

(Last) (First) (Middle)
C/O AGENUS INC.
3 FORBES ROAD

(Street)
LEXINGTON MA 02421

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 07/25/2025 A 2,745 A $5.96(2) 263,904 D
Common Stock 31,298 I See Footnote(3)
Common Stock 28,950 I See Footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 25, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
2. $5.96 is the closing price of our Common Stock on July 25, 2025, the last trading day for the payroll date for the pay period ending July 25, 2025.
3. Shares are held in Dr. Armen's IRA accounts.
4. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Remarks:
Chairman and Chief Executive Officer
/s/Christine M. Klaskin, as Attorney-in-Fact for Garo H. Armen 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What are EMCG shareholders voting on August 11, 2025?

Three proposals: extend the business-combination deadline to Aug 12 2026, amend the trust agreement accordingly, and allow meeting adjournment.

How much money is in Embrace Change’s trust account and what is the redemption price?

Approximately $26.9 million as of 25 Jul 2025, equating to about $12.08 per redeemable share.

Why is the sponsor behind on trust deposits?

It skipped eight $75k monthly contributions, leaving $675k unpaid; no reason is provided in the filing.

What happens if the extension and trust amendments are rejected?

The SPAC will cease operations, redeem all public shares within five business days, then liquidate and dissolve.

What vote thresholds are required for approval?

The charter extension needs a two-thirds majority of votes cast; the trust amendment needs >50 % of votes cast.

Can insiders redeem their shares?

No. The sponsor and insiders, holding 49.2 % of shares, have waived redemption rights for these proposals.
Agenus

NASDAQ:AGEN

AGEN Rankings

AGEN Latest News

AGEN Latest SEC Filings

AGEN Stock Data

174.10M
26.89M
1.31%
33.81%
13.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON